A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
A phase 3 trial of Sacituzumab tirumotecan, FOLFIRI, Paclitaxel / nab-paclitaxel in oesophageal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) is a phase 3 interventional study registered as NCT06356311 by Merck Sharp & Dohme LLC, with 450 participants planned, started 2024-05-03 and due to reach its primary completion in 2027-01-04. Interventions recorded: Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan, Paclitaxel, Docetaxel. Conditions listed: Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan
Shares Sacituzumab tirumotecan, Docetaxel, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With
Shares Sacituzumab tirumotecan, Docetaxel, Merck & Co. (MSD).
- TrialA Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Shares Sacituzumab tirumotecan, Docetaxel, Merck & Co. (MSD).
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Sacituzumab tirumotecan, Paclitaxel / nab-paclitaxel, Merck & Co. (MSD).
- TrialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer.
- TrialA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Shares Docetaxel, Merck & Co. (MSD), Oesophageal cancer.
- TrialSubstudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Oesophageal cancer.